Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data.Ravi A. Madan, Melissa L. Abel, Laura A. Sena et al.|Journal of Clinical Oncology|2026Cited by 0
Prospective monitoring of biochemically recurrent prostate cancer (BCR) using prostate specific membrane antigen (PSMA) imaging: 21-month follow-up.Ravi A. Madan, Melissa L. Abel, Esther Mena et al.|Journal of Clinical Oncology|2026Cited by 0